{Reference Type}: Case Reports
{Title}: Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer.
{Author}: McCullar B;Alloway T;Martin M;
{Journal}: J Thorac Dis
{Volume}: 9
{Issue}: 6
{Year}: Jun 2017
{Factor}: 3.005
{DOI}: 10.21037/jtd.2017.05.32
{Abstract}: Programmed death 1 (PD-1) inhibitors have been shown to increase overall survival in non-small cell lung cancer (NSCLC) patients. HIV patients have increased expression of PD-1 on their T-cell surfaces. We describe a patient with well-controlled HIV and NSCLC who underwent treatment with nivolumab and had a durable complete response (CR) with his viral load remaining undetectable. To date there is only one case report of a cancer patient with melanoma and with HIV treated with a programmed death ligand 1 (PD-L1) inhibitor. The majority of clinical trials involving PD-1 and PD-L1 inhibitors exclude HIV patients.